Image
Interactive Professor™

Clearing the Way in Atopic Dermatitis

A Case-Based Update on Pediatric Patients

Meeting Slides

Guidelines

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.

Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2020;34(12):2717-2744.

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.

Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(5):657-682.

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.

Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(6):850-878.

Patient Resources

International Eczema Council

Founded in late 2014, the International Eczema Council (IEC) is a global nonprofit organization led by dermatology experts on atopic dermatitis. The IEC is dedicated to increasing the understanding of atopic dermatitis and promoting its optimal management through research, education, and patient/family care.

Clinical Assessment Tools

Children’s Dermatology Life Quality Index (CDLQI)

CDLQI is 10-question patient-reported assessment tool designed to measure impact of any skin disease on the lives of children ages 4-16. (Lewis-Jones MS, Finlay AY. Br J Dermatol. 1995;132(6):942-949).

Patient-Oriented Eczema Measure (POEM)

The POEM is a patient-oriented, self-assessed measurement tool for monitoring aspects of atopic dermatitis in routine clinical practice or in the clinical trial setting. (Charman CR, et al. Arch Dermatol. 2004;140(12):1513-1519).

Suggested Readings

Atopic Dermatitis Overview and Pathogenesis

Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts.

Paternoster L, et al. J Allergy Clin Immunol. 2018:141(3):964-971.

Pathogenesis of atopic dermatitis.

Peng W, Novak N. Clin Exp Allergy. 2015;45(3):566-574.

Patient Burden and Comorbidities

The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis.

Chamlin SL, et at. Arch Pediatr Adolesc Med. 2005;159(8):745-750.

Association of atopic dermatitis and mental health outcomes across childhood: a longitudinal cohort study.

Kern C, et al. JAMA Dermatol. 2021;157(10):1200-1208.

‘His first word was “cream.”' The burden of treatment in paediatric atopic dermatitis—a mixed methods study.

O’Connor C, et al. Dermatol Ther. 2022;35(3):e15273.

Association between atopic dermatitis and suicidality: a systematic review and meta-analysis.

Sandhu JK, et al. JAMA Dermatol. 2019;155(2):178-187.

Increasing severity of early-onset atopic dermatitis, but not late-onset, associates with development of aeroallergen sensitization and allergic rhinitis in childhood.

Schoos AMM, et al. Allergy. 2022;77(4):1254-1262.

Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study.

Silverberg JI, et al. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2.

Comorbidities and the impact of atopic dermatitis.

Silverberg JI. Ann Allergy Asthma Immunol. 2019;123(2)144-151.

Management of Atopic Dermatitis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303.

Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial.

Blauvelt A, et al. JAMA Dermatol. 2021;157(9):1047-1055.

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.

Drucker AM, et al. Br J Dermatol. 2018;178(3):768-775.

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomized controlled phase 3 trials.

Guttman-Yassky E, et al. Lancet. 2021;397(10290):2151-2168.

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial.

Paller AS, et al. J Am Acad Dermatol. 2020;83(5):1282-1293.

Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial.

Silverberg JI, et al. JAMA Dermatol. 2020;156(8):863-873.

Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial.

Simpson EL, et al. JAMA Dermatol. 2020;156(1):44-56.

Activity
Clearing the Way in Atopic Dermatitis

A Case-Based Update on Pediatric Patients

Relevant Resources

Chronic Obstructive Pulmonary Disease, Asthma, or Both

Differential Diagnosis and Comprehensive Management Strategies

Improving Outcomes in Chronic Obstructive Pulmonary Disease

Optimizing Maintenance Therapy Across Healthcare Settings

Clearing the Air

Improving Outcomes for Patients with COPD

Comprehensive Management of Chronic Obstructive Pulmonary Disease

Collaborative Approaches to Guideline-Concordant Patient Care

Clinical Updates in the Management of Severe Asthma

New Strategies for Individualizing Long-term Care

Improving Outcomes in Severe Asthma

A New Era in Precision Medicine

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Caring for Patients with Severe Asthma

Evolving Best Practices to Optimize Outcomes

Clinical Issues in Severe Asthma

Consensus and Controversies on the Road to Precision Medicine

Clinical Updates in Rheumatoid Arthritis

New Strategies to Target Remission and Individualize Comprehensive Care

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Breathing Life Into COPD Management

Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care

Clinical Issues in Severe Asthma

Debates and Discussions About Personalizing Patient Management

Advancing the Care of Severe Asthma

Differential Diagnosis, Multidisciplinary Management, and Patient Engagement

Focusing on Patients With Severe Asthma

From Guideline Recommendations to Daily Clinical Decision-Making

Clearing the Air in Severe Asthma Management

Improving Patient Outcomes Through Shared Clinical Decision Making

Clinical Issues in Psoriasis

Debates and Discussions About Pustular Disease Subtypes

Looking Under the Surface in Pediatric Atopic Dermatitis

Collaborative Care for Better Patient Outcomes

Clearing the Air in Severe Asthma Management

Improving Patient Outcomes Through Shared Clinical Decision Making

Marching Forward in Atopic Dermatitis

Digging Deep on Shared Decision-Making

Airing It Out

A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis

COPD in Managed Care

The Clinical and Utilization Benefits of Exacerbation Prevention

Finding the Right Path in Severe Asthma

Mechanistic Insights and Emerging Treatment Options

COPD Cases and Conversations

A Focus on Exacerbation Prevention

Demystifying New Evidence for COPD Management

Best Practices for Primary Care

Updates on Chronic Rhinosinusitis with Nasal Polyps

Evolving Best Practices for Patient Management

Clinical SnapShots of Moderate-to-Severe Atopic Dermatitis

Pathophysiology, Multimodal Management, and Shared Clinical Decision Making

A Breath of Fresh Air in Pediatric Asthma

Shared Decision-making in the Era of Biologics

Swimming Upstream in Severe Asthma

New Pathways to Patient Management

Where are We Now In Moderate-to-Severe Asthma?

From Comprehensive Patient Evaluations to Individualized Evidence-based Care

COPD Cases & Conversations

Preventing COPD Exacerbations to Improve Outcomes

Comprehensive Management in COPD

A Whole Patient Case Series

Clinical Issues in COVID-19

Debates and Discussions about Monoclonal Antibody Therapies

Minimizing Patient Risks From COVID-19

An Update on Monoclonal Antibody Therapies

Cause for Alarm

New Avenues to the Management of Severe Asthma

Getting Up To Speed In Moderate-To-Severe Asthma

Evolving Best Practices for Pediatric Patients

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients

Answering the Call

Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema

Getting Low in Familial Hypercholesterolemia

Reducing LDL-C and a Lifetime of Cardiovascular Risk

Putting a Spotlight on Systemic Mastocytosis

A Multidisciplinary Look at Early Diagnosis and Management

Targeting Clear Horizons

Finding the Path in Chronic Rhinosinusitis with Nasal Polyps

Clinical Updates in COVID-19

Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment

Is It Systemic Mastocytosis?

Best Practices for Diagnosis and Management

Monoclonal Antibodies for COVID-19

An Update on Best Practices

Monoclonal Antibodies for COVID-19

New Avenues to Pre-Exposure Prophylaxis

Answering the Bell in Severe Asthma

New Pathways to Optimize Patient Outcomes

Clinical Issues in Severe Asthma

Debates and Discussions About New Upstream Treatment Avenues

Getting on Track in Atopic Dermatitis

An Interactive Educational Journey

A Call to Action

Monoclonal Antibodies for the Prevention and Treatment of COVID-19

What’s Next

Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis

Best Practices in COPD

Practical Updates on the 2023 GOLD Guidelines

Flexing Your Muscles in Familial Hypercholesterolemia

Best Practices for Screening, Diagnosis, and Management

What’s New in the Management of COVID-19

Incorporating New Data and Updated Guidelines Into Daily Practice

New Horizons in Severe Asthma

From the Airway Epithelium to Improved Patient Outcomes

Strengthening Your COVID-19 Management Technique

Exercising Best Practices for Hospitalized Patients

Making the Rounds on Systemic Mastocytosis

Accelerating Diagnosis and Treatment